迪瑞医疗科技股份有限公司 2024 年度独立董事述职报告 本人作为迪瑞医疗科技股份有限公司(以下简称"公司")的独立董事,严格 按照《公司法》《证券法》《上市公司治理准则》《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》《上市公司独立董事管理办法》 等法律、法规、规范性文件，以及《公司章程》《独立董事工作细则》的规定和 要求，在 2024 年度工作中诚实、勤勉、独立地履行职责，积极出席相关会议， 认真审议董事会各项议案，对公司重大事项发表了独立意见，切实维护了公司和 股东尤其是中小股东的利益，较好地发挥了独立董事作用。现就本人 2024 年度 履行独立董事职责情况汇报如下： 一、出席董事会及股东大会会议情况： 2024 年度，本人担任独立董事的期间公司共召开 4 次董事会，本人应参加 并实际参加董事会会议 4 次，不存在连续两次未亲自出席会议的情形，没有缺席 或委托其他独立董事代为出席会议并行使表决权的情形。本人出席 1 次股东大 会。本年度，本人对提交董事会的议案均认真审议，积极参与各议题的讨论并提 出合理建议，并结合自己的专业经验提出合理化建议，为公司董事会的科学决策 发挥了积 ...

2024 年度独立董事述职报告 本人作为迪瑞医疗科技股份有限公司(以下简称"公司")的独立董事,严格 按照《公司法》《证券法》《上市公司治理准则》《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》《上市公司独立董事管理办法》 等法律、法规、规范性文件，以及《公司章程》《独立董事工作细则》的规定和 要求，在 2024 年度工作中诚实、勤勉、独立地履行职责，积极出席相关会议， 认真审议董事会各项议案，对公司重大事项发表了独立意见，切实维护了公司和 股东尤其是中小股东的利益，较好地发挥了独立董事作用。现就本人 2024 年度 履行独立董事职责情况汇报如下： 行情况进行定期和不定期的检查和评估，保证公司内部控制的完整性、合理性。 与公司财务负责人、年审注册会计师进行了充分和有效地沟通，为公司财务管理 提出合理化的建议，充分运用自己的专业优势继续为公司生产经营与管理做好服 务，切实履行独立董事相关职责，规范公司运作。 迪瑞医疗科技股份有限公司 一、出席董事会及股东大会会议情况 2024 年度，本人担任独立董事的期间公司共召开 4 次董事会，本人应参加 并实际参加董事会会议 4 次，不存在连续两 ...

Financial Performance - The company's operating revenue for 2024 was ¥1,217,807,735.16, a decrease of 11.63% compared to ¥1,378,059,471.02 in 2023[17]. - The net profit attributable to shareholders for 2024 was ¥141,922,552.76, down 48.50% from ¥275,589,641.99 in 2023[17]. - The basic earnings per share for 2024 was ¥0.52, a decline of 48.51% from ¥1.01 in 2023[17]. - The total assets at the end of 2024 were ¥3,107,533,388.27, a decrease of 6.42% from ¥3,320,764,441.14 at the end of 2023[17]. - The net cash flow from operating activities for 2024 was -¥294,752,320.54, a significant decline from ¥224,498,855.12 in 2023, representing a change of -231.29%[17]. - The company reported a total non-operating income of 8,167,095.34 in 2024, a decrease of 38.5% from 13,152,818.30 in 2023[23]. - The fair value changes of financial assets and liabilities resulted in a gain of 615,898.19 in 2024, significantly lower than the 4,610,305.16 reported in 2023, reflecting an 86.7% decrease[23]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in Q3 2023, representing a 20% year-over-year growth[41]. - The company provided guidance for Q4 2023, expecting revenue to be between 1.6 billion and 1.7 billion, indicating a growth of 10% to 13%[41]. - The company reported a consistent increase in R&D activities, focusing on innovative testing kits and automated systems to improve laboratory workflows[44]. Market and Industry Outlook - The company operates in the in vitro diagnostics (IVD) industry, which is projected to grow to a market size of 288.15 billion RMB by 2030, capturing 33.2% of the global market[28]. - The aging population in China is expected to increase the demand for healthcare services, with 135 million elderly individuals receiving health services in 2023, representing a compound annual growth rate of 4.37% from 2020 to 2023[27]. - The government has introduced policies to enhance healthcare infrastructure, aiming for a 25% increase in equipment investment by 2027 compared to 2023[29]. - The company anticipates that the IVD sector will remain a high-growth area within the medical device market despite a slowdown in overall industry growth due to macroeconomic conditions and healthcare cost controls[28]. - The healthcare sector is expected to benefit from a series of government incentives aimed at improving the efficiency and accessibility of medical services[29]. Product Development and Innovation - The company has launched seven major product lines including urine analysis, biochemical analysis, immunoassay, blood cell analysis, coagulation analysis, gynecological secretion analysis, and integrated laboratory systems, all of which are developed in-house[32]. - The company has introduced over 60 new distribution channels in the domestic market, accounting for approximately 40% of domestic revenue, and has established partnerships with over 500 quality channels[34]. - The company has expanded its international market presence, exporting products to around 125 countries and regions, with a focus on localizing instrument and reagent production in key markets[35]. - The company has developed numerous high-end medical devices over 30 years, including advanced technologies for urine analysis and biochemical analysis, enhancing its competitive edge[37]. - The company launched several new products, including the BCA-2000 automatic coagulation analyzer and the BF-7600Plus blood cell analysis system, further solidifying its market position in high-end customer segments[38]. - The introduction of AI-based technologies in urine analysis aims to enhance automatic recognition of morphological components, improving early screening for kidney diseases[39]. - The company is focusing on developing low-temperature storage solutions for samples, which is anticipated to meet increasing market demand[44]. Financial Management and Strategy - The company has implemented a cash management strategy to maintain financial flexibility amid various challenges[50]. - The company is focusing on domestic market adjustments due to changes in channel client policies, leading to reduced procurement amounts and delayed payments from major clients[50]. - The company is advancing the localization of raw materials and modular production to respond to national procurement policies and enhance product cost-effectiveness[47]. - The company has established a comprehensive quality management system, achieving ISO9001 and ISO13485 certifications, and ensuring compliance with international standards[48]. - The company is actively expanding its international market presence, with a focus on localizing production and enhancing service teams[49]. Governance and Compliance - The company has a structured board with 9 members, including 3 independent directors, ensuring compliance with governance standards[122]. - The company has established a complete and independent business system, with no reliance on controlling shareholders or related parties in procurement, market, research and development, and production[125]. - The company has not provided guarantees for the debts of shareholders or related parties, maintaining full control and ownership of its assets[126]. - The audit committee conducted a thorough review of the 2023 annual report audit work and compliance with relevant regulations, ensuring the company's operational integrity[152]. - The company has established a value management system and an ESG management framework to enhance its market valuation[119]. Employee Management and Development - The total number of employees at the end of the reporting period was 1,821, including 1,727 at the parent company and 94 at major subsidiaries[156]. - The employee composition includes 635 production personnel, 735 sales personnel, 337 technical personnel, 31 financial personnel, and 83 administrative personnel[156]. - The company has established a comprehensive training system covering various dimensions, including job skills, professional knowledge, and management capabilities[159]. - The company has a performance-based salary system, focusing on rewarding high-performing employees through annual promotions and performance ratios[158]. - Continuous improvement in employee training ensures adaptability to the company's evolving needs[199]. Risk Management - The company recognizes the risks associated with new product development and technological innovation, committing to timely updates and market responsiveness to enhance competitiveness[111]. - The company faces risks from international market expansion due to uncertainties in import/export policies, international political relations, and exchange rate fluctuations[113]. - The company is committed to strengthening foreign exchange risk management and will utilize hedging tools to mitigate the impact of exchange rate volatility on financial results[115]. - The medical device industry faces strict regulatory risks, and the company will adapt its strategies to comply with evolving policies and maintain quality management[109].

证券代码：300396 证券简称：迪瑞医疗 公告编号：2025-001 迪瑞医疗科技股份有限公司 关于公司完成医疗器械生产许可证延续的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 企业负责人：王学敏 生产地址：长春市高新技术产业开发区云河街 95 号；长春市高新技术产业 开发区宜居路 3333 号；长春市高新区卓越东街与宜居路交汇北行 200 米创投高 新产业园 5#楼 生产范围： 2017 分类目录：II 类：22-01-血液学分析设备；22-02-生化分析 设备；22-03-电解质及血气分析设备；22-04-免疫分析设备；22-09-尿液及其他样 本分析设备；22-10-其他医用分析设备；22-15-检验及其他辅助设备；6840-体外 诊断试剂；III 类：6840-体外诊断试剂*** 住所：长春市高新技术产业开发区云河街 95 号 许可期限：自 2025 年 2 月 28 日至 2030 年 2 月 27 日 迪瑞医疗科技股份有限公司（以下简称"公司"）于近日取得了吉林省药品 监督管理局换发的《医疗器械生产许可证》（许可证编号：吉药监械生产许 2 ...

第六届监事会第一次临时会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：300396 证券简称：迪瑞医疗 公告编号：2024-050 迪瑞医疗科技股份有限公司 具体内容详见巨潮资讯网（www.cninfo.com.cn）《关于开展应收账款保理业 务的公告》。 表决结果：3 票同意，0 票反对，0 票弃权，同意票占有效表决权 100%。 特此公告。 迪瑞医疗科技股份有限公司监事会 2024 年 12 月 25 日 迪瑞医疗科技股份有限公司（以下简称"公司"）第六届监事会第一次临时会 议（以下简称"本次会议"）于 2024 年 12 月 25 日在公司以现场及通讯方式召开， 本次会议由监事会主席熊玲霞主持，应出席公司会议的监事 3 人，实际出席公司 会议的监事 3 人。根据《公司章程》的规定，本次会议通知于 2024 年 12 月 17 日以现场送达及通讯方式发出，会议召开符合《中华人民共和国公司法》和《公 司章程》的规定，会议合法有效。 与会监事经认真审议，以现场及通讯表决方式审议通过了如下决议： 一、审议并一致通过《关于开展应收账款保理业 ...

证券代码：300396 证券简称：迪瑞医疗 公告编号：2024-049 迪瑞医疗科技股份有限公司 第六届董事会第一次临时会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 迪瑞医疗科技股份有限公司（以下简称"公司"）第六届董事会第一次临时会 议（以下简称"本次会议"）于 2024 年 12 月 25 日在公司以现场及通讯方式召开。 本次会议由董事长宋清先生主持，应出席公司会议的董事 9 人，实际出席董事 9 人，公司监事、高级管理人员列席会议。根据《公司章程》的规定，本次会议通 知于 2024 年 12 月 17 日以现场及电子邮件送达方式发出，会议召开符合《中华 人民共和国公司法》《公司章程》的规定，会议合法有效。 与会董事经认真审议，以现场或通讯表决方式审议通过了如下决议： 一、审议并一致通过《关于开展应收账款保理业务的议案》 具体内容详见巨潮资讯网（www.cninfo.com.cn）《关于开展应收账款保理业 务的公告》，敬请广大投资者查阅。 二、审议并一致通过《关于向银行申请授信额度的议案》 根据公司生产经营需要，公司拟向中信银行股份有限公司 ...

关于开展应收账款保理业务的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：300396 证券简称：迪瑞医疗 公告编号：2024-051 迪瑞医疗科技股份有限公司 迪瑞医疗科技股份有限公司（以下简称"公司"）于 2024 年 12 月 25 日召开 了第六届董事会第一次临时会议，审议通过了《关于开展应收账款保理业务的议 案》等事项。公司拟开展应收账款保理业务，保理额度不超过人民币 6,000 万元 （含）。 根据《深圳证券交易所创业板股票上市规则》和《公司章程》等规定，本次 公司开展应收账款保理业务不属于关联交易，亦不属于《上市公司重大资产重组 管理办法》中规定的重大资产重组。本次应收账款保理业务在公司董事会审批权 限内，无需提交股东大会审议。具体内容如下： 1、保理类型：应收账款无追索权保理方式，具体以保理合同约定为准。 2、保理额度：使用额度不超过人民币 6,000 万元（含），保理期限内额度可 循环使用。 3、保理额度有效期：自董事会审议通过之日起 12 个月内，具体每笔保理业 务期限以单项保理业务约定期限为准。 4、保理融资的费率：根据市 ...

证券代码：300396 证券简称：迪瑞医疗 公告编号：2024-048 迪瑞医疗科技股份有限公司 关于持股 5%以上股东及一致行动人减持股份比例达到 1% 暨提前终止减持计划的公告 持股 5%以上的股东宋洁、宋勇、易湘苹保证向本公司提供的信息内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 迪瑞医疗科技股份有限公司（以下简称"迪瑞医疗"或"公司"）2024 年 10 月 27 日披露了《关于持股 5%以上股东减持股份预披露公告》。"持股 5%以上股 东宋洁女士及其一致行动人宋勇先生、易湘苹女士（上述股东合计持有公司股份 36,853,103 股，占公司总股本比例 13.51%)计划自本减持计划公告之日起十五个 交易日后的三个月内（即 2024 年 11 月 19 日至 2025 年 2 月 18 日）以竞价或大 宗交易方式减持公司股份合计不超过 5,410,000 股，减持股份数量不超过公司目 前总股本 1.98%。其中，通过竞价方式减持的，宋洁及一致行动人任意连续 90 个自然日内以竞价方式减持股份的总数不超过公司股份总数的 1 ...

Investment Rating - The report maintains a "Recommend" rating for Dirui Medical (300396) with a target price of 22 CNY, compared to the current price of 17.28 CNY [1] Core Views - Dirui Medical's performance is under temporary pressure, with a focus on the installation of high-speed machines and the increase in the sales proportion of reagent products [2] - The company's domestic business in Q3 2024 focused on basic medical instruments, leading to a decline in gross margin due to product structure and medical procurement policies [2] - Overseas business is recovering as planned, with some localization projects already operational, shortening the reagent supply cycle and reducing transportation costs [2] - The company plans to accelerate the installation of high-speed machines and promote balanced development of instruments and reagents to ensure stable growth [2] - Comprehensive cost control measures have achieved initial results, with a significant decrease in management expenses by 51.80% in Q3 2024 [2] - Product registration is progressing steadily, with 4 medical device change registration documents and 22 medical device registration certificates obtained in August 2024, enhancing the company's product competitiveness [2] Financial Performance - In Q1-Q3 2024, Dirui Medical's revenue was 1.175 billion CNY (+12.10% YoY), with net profit attributable to shareholders of 193 million CNY (-17.80% YoY) [1] - In Q3 2024, revenue was 297 million CNY (-15.97% YoY), with net profit attributable to shareholders of 27 million CNY (-62.28% YoY) [1] - The company's sales expenses in Q3 2024 were 54 million CNY (-0.60% YoY), R&D expenses were 33 million CNY (-4.64% YoY), and management expenses were 9 million CNY (-51.80% YoY) [2] - The management expense ratio in Q3 2024 was 3.16%, a decrease of 2.34 percentage points [2] Financial Forecast - The report forecasts Dirui Medical's net profit attributable to shareholders for 2024-2026 to be 280 million, 380 million, and 520 million CNY, with YoY growth rates of +2.2%, +35.5%, and +35.8% respectively [2] - EPS for 2024-2026 is expected to be 1.03, 1.40, and 1.90 CNY, with corresponding P/E ratios of 17x, 12x, and 9x [2] - The DCF model estimates the company's overall valuation at 6 billion CNY, corresponding to a target price of 22 CNY [2] Market Performance - Dirui Medical's total market capitalization is 4.712 billion CNY, with a circulating market capitalization of 4.708 billion CNY [4] - The company's 12-month high and low prices are 32.80 CNY and 12.92 CNY respectively [4] Product and Market Strategy - The company is focusing on the localization of overseas markets, with some projects already operational, which is expected to improve the proportion of reagent sales in international markets [2] - Dirui Medical is advancing the development of high-speed machines and reagent products, aiming to optimize its product structure and enhance market competitiveness [2]

Summary of the Conference Call Industry or Company Involved - The conference call pertains to the **Jilin Province listed companies** and their efforts to enhance investor confidence and communication through an online event organized by the **Jilin Securities Association** and **Shenzhen Panorama Network Co., Ltd** [1][10]. Core Points and Arguments - The event titled **"Promoting High-Quality Development to Boost Investor Confidence 2025"** aims to improve the intellectual level of listed companies in Jilin and establish a good communication mechanism between companies and investors [1]. - High-level executives from various listed companies, including chairpersons, general managers, financial directors, and board secretaries, participated in the online interaction with investors, addressing concerns regarding the **2024 annual reports**, risk prevention, investor protection, and sustainable development [1][10]. - The event facilitated a total of **872 questions** answered by company representatives, showcasing effective interaction between listed companies and investors [10]. Other Important but Possibly Overlooked Content - The online format of the event allows for a more comprehensive understanding of the participating companies by investors, leveraging the advantages of internet-based face-to-face communication [3]. - Continuous communication channels will remain open post-event, allowing investors to raise further inquiries through the Panorama Network's platform [10]. - The list of participating companies includes notable names such as **Jilin Communication, Jilin Aodong, Jilin High-Speed, and others**, indicating a diverse representation from the Jilin province [2].